Loading
A phase 2 trial of PF-07248144, Fulvestrant, Letrozole in prostate cancer and non-small-cell lung cancer, run by Pfizer, now recruiting.
Study of PF-07248144 in Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT04606446 by Pfizer, with 320 participants planned, started 2020-11-16 and due to reach its primary completion in 2029-07-13. Interventions recorded: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060. Conditions listed: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Atirmociclib, Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, Vepdegestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, Palbociclib, Pfizer (incl. Seagen).
Shares PF-07248144, Pfizer (incl. Seagen).
Shares Vepdegestrant, Palbociclib, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.